Aviva Investors has flagged three of its funds as failing to deliver value for customers, though said no changes will be made ...

Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Malgré les reculs politiques, de nombreuses grandes entreprises européennes publient déjà leurs reportings CSRD.

Novo Nordisk is seeking as much as US$830 million in damages in a Singapore court, saying it was misled by a local biotech ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

Novo Nordisk is seeking up to US$830 million ($1.3 billion) in damages from KBP Biosciences arguing it was misled by the ...

Tariffs targeted at countries — reciprocal or regular — will likely be paid by multinational companies, dampening the outlook ...

A summary of current health news highlights a bird flu outbreak in Canada, halted HIV vaccine trials in South Africa, a legal ...